The interleukin-6 receptor antagonist sarilumab (Kevzara) will be indicated in adults who have had an inadequate response to corticosteroids or could not tolerate a corticosteroid taper.
The US Food and Drug Administration approved sarilumab today for the treatment of polymyalgia rheumatica in adults who have had an inadequate response to corticosteroids or could not tolerate a corticosteroid taper, joint developers
. The drug is the first and only FDA-approved biologic treatment for this inflammatory rheumatic disease. , an interleukin-6 receptor antagonist, in May 2017 for the treatment of moderate-to-severe active rheumatoid arthritis in adults who do not respond well or have an intolerance to disease-modifying antirheumatic drugs , like methotrexate.SAPHYR trial
in patients with corticosteroid-resistant, active PMR. In the randomized, double-blind, placebo-controlled study, 59 participants received 200 mg of sarilumab plus a 14-week taper of corticosteroid treatment and 58 participants received placebo every 2 weeks along with a 52-week taper of corticosteroid treatment.
After 1 year, 28% of sarilumab patients achieved sustained remission, compared with 10% of the placebo group (
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
U.S. FDA approves Reata's rare genetic disorder drugThe U.S. Food and Drug Administration on Tuesday approved Reata Pharmaceuticals Inc's drug for the treatment of a rare genetic disorder that causes progressive damage to the nervous system, sending shares up nearly 160% after the bell.
Consulte Mais informação »
Paving the way for the world's first RSV vaccine, FDA advisers recommend shot from PfizerBREAKING: FDA advisers recommend that the agency approve the country’s first RSV vaccine for older people, a shot from Pfizer for adults ages 60 and up.
Consulte Mais informação »
FDA Advisors Recommend First-Ever RSV Vaccine From Pfizer, Despite Possible Guillain-Barre RisksSeveral FDA advisors said there could be a significant safety issue after two vaccine recipients out of about 20,000 developed Guillain-Barre syndrome.
Consulte Mais informação »
FDA Considers Two Drugmakers for First RSV VaccineAn FDA advisory panel is considering two drugmakers to make the first respiratory syncytial virus (RSV) vaccine. Pfizer and GSK seek to lead the market that could be worth between $5 billion and $10 billion.
Consulte Mais informação »